|
|
|
|
| LEADER |
03156nam a2200373 u 4500 |
| 001 |
EB000944074 |
| 003 |
EBX01000000000000000737664 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150223 r ||| eng |
| 020 |
|
|
|a 9780309285964
|
| 020 |
|
|
|a 0309285968
|
| 100 |
1 |
|
|a Olson, Steve
|
| 245 |
0 |
0 |
|a The global crisis of drug-resistant tuberculosis and leadership of China and the BRICS
|h Elektronische Ressource
|b challenges and opportunities : summary of a joint workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences
|c Steve Olson, Rebecca A. English, and Anne B. Claiborne, rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies
|
| 260 |
|
|
|a Washington, D.C.
|b The National Academies Press
|c 2014, [2014]
|
| 300 |
|
|
|a 1 PDF file (xxi, 195 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a China
|
| 653 |
|
|
|a Global Health
|
| 653 |
|
|
|a Antitubercular Agents
|
| 653 |
|
|
|a Tuberculosis, Multidrug-Resistant
|
| 653 |
|
|
|a International Cooperation
|
| 700 |
1 |
|
|a English, Rebecca A.
|e [author]
|
| 700 |
1 |
|
|a Claiborne, Anne B.
|e [author]
|
| 710 |
2 |
|
|a Institute of Medicine (U.S.)
|b Forum on Drug Discovery, Development, and Translation
|
| 710 |
2 |
|
|a Institute of Medicine (U.S.)
|
| 710 |
2 |
|
|a Zhongguo ke xue yuan
|b Wei sheng wu yan jiu suo
|
| 710 |
2 |
|
|a Global Crisis of Drug-Resistant Tuberculosis and Leadership of the BRICS Countries : Challenges and Opportunities (Workshop) (2013, Beijing, China)
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 500 |
|
|
|a Title from PDF title page
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK174841
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.
|